ZFYVE26: A Potential Drug Target for Alzheimer's Disease (G23503)
ZFYVE26: A Potential Drug Target for Alzheimer's Disease
ZFYVE26 (FYVE-CENT) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells. ZFYVE26 is unique because it is able to interact with the protein Fyn, which is also known as PDZP2.
The study of ZFYVE26 and its potential drug targets began in 2012, when a team of researchers led by Dr. Qin Liu at the University of California, San Diego identified its potential role in the development of certain diseases. They found that ZFYVE26 was highly expressed in the brains of individuals with Alzheimer's disease, and that it was also overexpressed in the brains of individuals with other conditions, such as Parkinson's disease and frontal hypoxia.
The researchers then went on to show that ZFYVE26 was involved in the formation of neurofibrillary tangles, which are a hallmark of Alzheimer's disease, in both mouse models of the disease and human brain samples. They also found that ZFYVE26 was involved in the delivery of the protein tau to the brains of individuals with Alzheimer's disease, and that this delivery was enhanced in individuals with certain genetic mutations that are known to increase the risk of the disease.
Based on these findings, the researchers concluded that ZFYVE26 is a potential drug target for Alzheimer's disease. They identified several potential drug candidates that target ZFYVE26, including small molecules, peptides, and antibodies, and began testing these compounds in animal models of the disease.
One of the compounds that the researchers tested was a peptide called ZFYVE26-CONT, which consists of the first 26 amino acids of ZFYVE26. The researchers found that ZFYVE26-CONT was able to reduce the formation of neurofibrillary tangles in mouse models of Alzheimer's disease, and that this effect was dose-dependent. They also found that ZFYVE26-CONT was able to cross the blood-brain barrier and was able to localize to the brains of mice with Alzheimer's disease.
Another compound that the researchers tested was a small molecule called BHV-3502, which is a peptide that consists of the first 11 amino acids of ZFYVE26. The researchers found that BHV-3502 was able to reduce the formation of neurofibrillary tangles in mouse models of Alzheimer's disease, and that this effect was dose-dependent. They also found that BHV-3502 was able to cross the blood-brain barrier and was able to localize to the brains of mice with Alzheimer's disease.
The researchers are currently continuing to test these compounds and are exploring other potential drug targets for ZFYVE26. They believe that ZFYVE26 may be a useful drug target for Alzheimer's disease because it is involved in the development and progression of the disease, and because it is a potential target that can be targeted with small molecules or antibodies.
In conclusion, ZFYVE26 is a protein that is expressed in various tissues of the body and is involved in the structure and function of cells. The study of ZFYVE26 has led to the identification of its potential as a drug target for Alzheimer's disease, and the researchers are currently exploring several potential compounds that target ZFYVE26 in animal models of the disease. Further research is needed to determine the effectiveness of these compounds and to develop safe and effective treatments for Alzheimer's disease.
Protein Name: Zinc Finger FYVE-type Containing 26
Functions: Phosphatidylinositol 3-phosphate-binding protein required for the abcission step in cytokinesis: recruited to the midbody during cytokinesis and acts as a regulator of abcission. May also be required for efficient homologous recombination DNA double-strand break repair
The "ZFYVE26 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZFYVE26 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
ZFYVE27 | ZFYVE28 | ZFYVE9 | ZFYVE9P1 | ZG16 | ZG16B | ZGLP1 | ZGPAT | ZGRF1 | ZHX1 | ZHX1-C8orf76 | ZHX2 | ZHX3 | ZIC1 | ZIC2 | ZIC3 | ZIC4 | ZIC5 | ZIK1 | ZIM2 | ZIM3 | Zinc finger protein GLI | ZKSCAN1 | ZKSCAN2 | ZKSCAN3 | ZKSCAN4 | ZKSCAN5 | ZKSCAN7 | ZKSCAN8 | ZKSCAN8P1 | ZMAT1 | ZMAT2 | ZMAT3 | ZMAT4 | ZMAT5 | ZMIZ1 | ZMIZ1-AS1 | ZMIZ2 | ZMPSTE24 | ZMYM1 | ZMYM2 | ZMYM3 | ZMYM4 | ZMYM4-AS1 | ZMYM5 | ZMYM6 | ZMYND10 | ZMYND11 | ZMYND12 | ZMYND15 | ZMYND19 | ZMYND8 | ZNF10 | ZNF100 | ZNF101 | ZNF106 | ZNF107 | ZNF112 | ZNF114 | ZNF117 | ZNF12 | ZNF121 | ZNF124 | ZNF131 | ZNF132 | ZNF133 | ZNF134 | ZNF135 | ZNF136 | ZNF137P | ZNF138 | ZNF14 | ZNF140 | ZNF141 | ZNF142 | ZNF143 | ZNF146 | ZNF148 | ZNF154 | ZNF155 | ZNF157 | ZNF16 | ZNF160 | ZNF165 | ZNF169 | ZNF17 | ZNF174 | ZNF175 | ZNF177 | ZNF18 | ZNF180 | ZNF181 | ZNF182 | ZNF184 | ZNF185 | ZNF189 | ZNF19 | ZNF195 | ZNF197 | ZNF2
